MEDIBANK PRIVATE LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.62 AUD | -0.28% |
|
-2.16% | +1.69% |
| May. 20 | Medibank Private Raises Give-Back Commitment to AU$305 Million | MT |
| May. 08 | Jarden Adjusts Medibank Private Price Target to AU$3.85 from AU$3.80, Keeps at Neutral | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company is one of the best yield companies with high dividend expectations.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +1.69% | 6.68B | C+ | ||
| +12.37% | 9.62B | B- | ||
| +8.60% | 5.71B | C | ||
| +140.44% | 5.34B | - | ||
| -3.65% | 2.31B | B+ | ||
| -1.54% | 1.27B | C | ||
| +2.13% | 863M | - | D+ | |
| +76.39% | 667M | - | C | |
| -2.14% | 148M | - | - | |
| -16.30% | 63.74M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MPL Stock
- Ratings Medibank Private Limited